Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryAn evidence-based causative classification system for acute ischemic strokeAntiplatelet agents versus control or anticoagulation for heart failure in sinus rhythmAnticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutterAnticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attackEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesThe Ischemic Stroke Genetics Study (ISGS) Protocol.Atrial fibrillation in a primary care practice: prevalence and managementOccurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient recordsProtocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN893A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new systemAnticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatranEmerging Tools for Stroke Prevention in Atrial FibrillationStroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe evolution of anticoagulant therapyLeft Atrial Appendage: Physiology, Pathology, and Role as a Therapeutic TargetMore outcomes than trials: a call for consistent data collection across stroke rehabilitation trialsDeveloping an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillationDirect thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillationFrequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillationPreventable stroke and stroke preventionLong term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research databaseOutcomes in the management of atrial fibrillation: clinical trial results can apply in practiceImportance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paperNew treatment options for stroke prevention in atrial fibrillationAntiplatelet agents versus control or anticoagulation for heart failure in sinus rhythmPreference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision makingAtrial fibrillation and stroke: four treatment controversiesTreatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome)Case report of paroxysmal atrial fibrillation and anticoagulation.The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillationThromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillationUnresolved issues in anticoagulant therapyShould aspirin be continued in patients started on warfarin?Breaks in continuity of care and the rural senior transferred for medical care under regionalisation
P2860
Q22241786-5372A7F3-EF52-44B6-AB45-8EC27DAD9258Q22337438-3526C9DE-737B-4C72-A301-90C3413C9F71Q24185800-8EC4824A-CDAF-49F7-A5A6-5F30BDB5A399Q24245613-85C8BE9E-02D9-4C9D-871B-7CD174CD2738Q24245863-7E97CB3A-373F-4536-9ECD-C45A94CDB29BQ24632951-F75295BC-593E-4383-BE7C-CEE3D02BA787Q24794936-827C2C61-47A8-49CF-8032-8A8CDE9BB15EQ24795377-A3B42960-968C-40F3-A24A-B5820FBDE212Q24800847-A677E62D-45AE-4B8C-B6F7-B09F68576BC0Q24801915-044EAA2D-681F-4CFA-9C5F-A7D6E1C23C34Q24803243-634DEBF5-F23A-4713-B0F5-18CD3877C28DQ24805951-68BEEA63-61B1-49C1-B3A9-04BE2B667B7BQ24807132-4EF9BDA0-D93F-49A5-851D-9D9EC53302B4Q26765023-F0BF8AD9-8CB5-440E-98EE-D65A599AA041Q26771564-C397BF8B-D205-4D13-A928-2ABC444B9781Q26771859-A33E9DAB-5264-4E25-83EF-D68FEFC52B81Q26799847-5D15F795-984D-4F01-99F9-46CE8767BF06Q27009182-E2AFA214-0A1C-4016-BC83-C5E918C7BD22Q27321275-A4AB2BA5-4488-43AA-91E8-E8BE3A4BA6FAQ27341873-E5332954-1643-410B-A277-7ED074D14E0DQ28175307-835DC25C-087B-4E1A-AA14-F5CE00C0FD59Q28176666-8073DDEA-4921-4A7B-A4F9-04CFCBC46F29Q28183704-8061FD89-E938-499D-BBD1-1720CEF6B0FFQ28187602-2B66CB55-5E47-46AA-A053-B54C80929E65Q28187842-C57921EF-2CC9-4BAA-9661-8E2519AD1CA3Q28188181-1F4ED49A-7488-42BC-90CC-EAFD193C6FA4Q28188553-B44CAA27-22AD-45BF-85C7-DE6B8A37936DQ28188630-ED8537CF-EE53-4528-963C-A43798D7A324Q28190407-48902DF7-0B51-43AC-921E-D0EC4CFC3C62Q28191116-A9291CC6-8629-4734-9C8B-F60C1ACBAB69Q28191848-C8C11FE9-57F4-4AF1-A51B-ADED17201AE1Q28192640-0DBCF37D-F4C1-48DE-BB83-0C7BC7B62793Q28193706-140F0CB8-709D-4290-ABCA-B0B641DC753DQ28194085-BCBA86A2-4BF5-408E-90BC-E4AC4E75F5BDQ28194361-7D9C8D97-F200-4C84-872D-6204D7385E74Q28195334-0BD49748-CBD6-4CEB-BFF5-D729EAF65616Q28196521-36696710-A529-4DFD-B8A6-0CA741FF0E6AQ28196778-3377E967-82EC-4A9F-9EA7-AE394BCF1571Q28199065-0078CA78-127A-472A-B415-052EC7F79DE9Q28200084-B4C27A1E-A85A-43CF-BDF7-5A5128DE19D7
P2860
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Antithrombotic therapy to prev ...... fibrillation: a meta-analysis.
@ast
Antithrombotic therapy to prev ...... fibrillation: a meta-analysis.
@en
type
label
Antithrombotic therapy to prev ...... fibrillation: a meta-analysis.
@ast
Antithrombotic therapy to prev ...... fibrillation: a meta-analysis.
@en
prefLabel
Antithrombotic therapy to prev ...... fibrillation: a meta-analysis.
@ast
Antithrombotic therapy to prev ...... fibrillation: a meta-analysis.
@en
P2093
P1476
Antithrombotic therapy to prev ...... fibrillation: a meta-analysis.
@en
P2093
P304
P356
10.7326/0003-4819-131-7-199910050-00003
P407
P577
1999-10-01T00:00:00Z